Search - tctmd.com

Displaying 41 - 60 of 725

Sort: Relevancy | Date

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Industry News

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

January 30, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

Shelley Wood

September 02, 2024

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Advertisement

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

AHA Statement Outlines Cardiac Contributions to Brain Health

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Statins Are Cost-effective in the Elderly

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content